Business Wire

Patient Safety Movement Foundation Calls for Action in Advance of Second Annual #UniteForSafeCare Event

31.8.2021 15:00:00 EEST | Business Wire | Press release

Share

The second annual #UniteForSafeCare event is scheduled for Friday, September 17th in conjunction with World Patient Safety Day. The event is hosted by the Patient Safety Movement Foundation (PSMF) and co-convened with The Leapfrog Group to bring global awareness to the lack of safety in healthcare and the fact that more than three million people die each year as the result of unsafe care. The event will explore how the public and other stakeholders can call for high reliability in healthcare, as well as the World Health Organization’s 2021 theme of “safe maternal and newborn care.”

As part of this year’s event, leadership from the Patient Safety Movement Foundation will coordinate demonstrations on both the east and west coasts in honor of World Patient Safety Day. Patient Safety Movement Foundation CEO Dr. David B. Mayer will continue his walk which began in February 2020 to raise awareness of patient and healthcare worker safety. Since starting, he has covered over 3,400 miles and been joined by families impacted by patient harm in over 30 states. This year’s walk will begin on September 11th on the 20th anniversary of the terrorist attacks to honor the lives lost and impacted, and will start in Gettysburg, Penn. Gettysburg was chosen as the starting point due to its strong visual representation of lives lost during the American Civil War drawing parallel to the lives lost each day due to unsafe care. The walk will finish in front of the White House in a call for action before continuing on to Capitol Hill.

“Over 8,220 people die every day in hospitals worldwide from unsafe care that’s six people every minute and the pandemic is making the delivery of safe care even harder,” stated Mayer. “This annual event allows us to bring the community and stakeholders together to raise awareness of this issue and advocate for change to make zero preventable deaths a reality.”

Here are the ways you can get involved this year:

  • Attend the free virtual event: The virtual event will occur from 11 a.m. to 3:15 p.m. PDT on Friday, September 17th. At the event, attendees will have the chance to hear from Patient Safety Movement Foundation leadership, as well as over 20 speakers including Tedros Adhanom Ghebreyesus, PhD, MSc, director-general of the World Health Organization. Dariush Eghbali, an Iranian artist and humanitarian, will be performing and attendees will have the opportunity to network and access exhibitor booths. In addition, there will be a panel with the showrunner and cast of Peacock’s TV series “Dr. Death” followed by a segment to memorialize the patients we’ve lost due to preventable harm. Attendees will have the opportunity to bid on items up for auction – including a private screening and Q&A session with the filmmaker of HBO’s “Bleed Out,” as well as a conversation with Patrick Macmanus, the showrunner of “Dr. Death.” All proceeds of the auction support awareness and education initiatives. To see the full schedule and RSVP, visit: https://patient.sm/B15-UFSC.
  • Host your own walk: Download the Charity Miles app and walk on your own or invite your coworkers and community to dedicate a walk, run, bike or any movement to show your support for the cause.
  • Make a donation : Donations help fund awareness and education campaigns throughout the year. Individuals can make donations in honor of loved ones who have been affected by preventable medical harm. PSMF will plant an orange flag in Orange County or Washington D.C. for any donation of $10 or more. To help PSMF reach its goal of $250,000, visit: https://patient.sm/PR-UFSC-Donate.
  • Share on social: Spread the word and help advocate for safer care by increasing awareness on social media. Use the hashtag #uniteforsafecare or translate it into any language to keep the conversation going globally.
  • Send in your art: New this year, a virtual patient, family and survivor art gallery is available for individuals to share personal expressions of the emotions they felt as they navigated experiences with medical errors – whether it ended in tragedy or in joy. The art will be displayed along with a place to share the meaning behind the piece. To view the art or submit your own piece, visit: https://patient.sm/B15-Artwork.
  • Wear and “light up” orange: Show your support by wearing orange, the official World Patient Safety Day color, or lighting up your house, a local monument or business orange. Share your photos on social media between September 13th and September 17th. You can also purchase official campaign t-shirts and hats: https://patient.sm/B15-Shop.

This year’s event is made possible by the generous sponsorship of Dr. Steven J. Barker, Gordon & Betty Moore Foundation, HealthySimulation.com, Jewish Healthcare Foundation, Josie King Foundation, Kaiser Permanente, Liamar Healthcare, Medstar Health Institute for Quality and Safety and Teletracking. To learn more about #UniteForSafeCare, visit: https://patientsafetymovement.org/unite-for-safe-care/home/.

About the Patient Safety Movement Foundation: Each year, more than 200,000 people die in U.S. hospitals and more than three million globally as a result of unsafe care. The Patient Safety Movement Foundation (PSMF) is a global non-profit with a vision to eliminate preventable patient harm and death across the globe by 2030. PSMF unites patients, advocates, healthcare providers, medical technology companies, government, employers and private payers in support of this cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org, and follow PSMF on LinkedIn, Twitter, Instagram and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Leslie Licano, Beyond Fifteen Communications, Inc.
psmf@beyondfifteen.com | (949) 733-8679 ext.101

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye